TKM-130803, a small interfering RNA lipid nanoparticle product, has been developed for the treatment of Ebola virus disease (EVD), but its efficacy and safety in humans has not been evaluated.
Methods and Findings
In this single-arm phase 2 trial, adults with laboratory-confirmed EVD received 0.3 mg/kg of TKM-130803 by intravenous infusion once daily for up to 7 d. On days when trial enrolment capacity was reached, patients were enrolled into a concurre...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's version
- Public Library of Science Publisher's website
- PLoS Medicine Journal website
- Publication date:
- Acceptance date:
1549-1676 and 1549-1277
- Pubs id:
- Local pid:
- Copyright holder:
- Dunning et al
- Copyright date:
- © 2016 Dunning et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Experimental treatment of Ebola virus disease with TKM-130803: A single-arm phase 2 clinical trial.
If you are the owner of this record, you can report an update to it here: Report update to this record